2024-514580-26-00招募中2 期
An open label, single-arm, phase 2 study of neoadjuvant PEMbrolizumab before radical PROstatectomy (PEM-PRO) in high-risk prostate cancer patients
Ospedale San Raffaele S.r.l.1 个研究点 分布在 1 个国家目标入组 59 人开始时间: 2024年10月8日最近更新:
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 59
- 试验地点
- 1
- 主要终点
- A reduction of 50% in the rate of node positive patients compared to what currently reported in the literature represents the main endpoint of the study (rate of pN0 of 85 vs. 70%)
研究概览
简要总结
To assess if neoadjuvant therapy with pembrolizumab is associated with a reduction in the rate of lymph node invasion in prostate cancer patients at high risk of recurrence after surgery.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of prostate cancer
- •PCa detected at prostate biopsy with a risk of lymph node invasion higher than 5% according to the Briganti nomogram
- •The participant should be fit and planned for RP and ePLND
- •The participant (or legally acceptable representative if applicable) provides written informed consent for the trial
- •Did not start novel therapies within the 4 weeks before the beginning of the study
- •Willingness to use contraception during study treatment
排除标准
- •Has received prior systemic anti-cancer therapy including investigational agents prior to allocation.
- •Clinically relevant hepatic or renal diseases
- •Onset of cerebral diseases within 6 months before the study beginning
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject’s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
- •Severe hypersensitivity (Grade 3) to pembrolizumab and/or any of its excipients
- •Unable to complete the diagnostic investigations required per protocol
- •Evidence of metastases at preoperative imaging
- •Evidence of lymph node invasion before surgery
- •Life expectancy shorter than 12 months
- •History of chemotherapy
- •History of brachytherapy or EBRT
- •Cardiovascular diseases not controlled by medical therapy
- •Hearth failure
结局指标
主要结局
A reduction of 50% in the rate of node positive patients compared to what currently reported in the literature represents the main endpoint of the study (rate of pN0 of 85 vs. 70%)
A reduction of 50% in the rate of node positive patients compared to what currently reported in the literature represents the main endpoint of the study (rate of pN0 of 85 vs. 70%)
次要结局
未报告次要终点
研究者
Francesco Montorsi
Scientific
Ospedale San Raffaele S.r.l.
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
An open label, single-arm, phase 2 study od neoadjuvant nivolumab and nab-paclitaxel before cystectomy for patients with muscle-invasive bladder cancermuscle-invasive bladder cancerMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005050-20-ITOSPEDALE SAN RAFFAELE29
进行中（未招募）
1 期
Phase II study, open label, single arm, evaluating the efficacy of neoadjuvant eribulin mesylate in patients with triple negative breast cancerEUCTR2012-004956-12-ITISTITUTO NAZIONALE PER LA CURA TUMORI48
进行中（未招募）
1 期
A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in high risk, surgically resectable, stage III Cutaneaous Squamous Cell Carcinomahigh risk, surgically resectable, stage III Cutaneous Squamous Cell CarcinomaMedDRA version: 21.1Level: PTClassification code 10041834Term: Squamous cell carcinoma of skinSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001469-34-ITFONDAZIONE MELANOMA ONLUS25
已完成
2 期
Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative MammacarcinomaMedDRA - 10006187: Primary mamma carcinomaC50Malignant neoplasm of breastDRKS00000162niversität Leipzig152
进行中（未招募）
1 期
Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative MammacarcinomaPhase-IIb-Studie zur Erfassung der Effektivität einer neoadjuvanten Chemotherapie mit Docetaxel, Epirubicin und Cyclophosphamid (TEC) bei Patientinnen mit primärem HER- 2 neu negativem MammakarzinomPrimary mamma carcinomaMedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003064-19-DEniversität Leipzig